Clinical Trials
32 results for Prostate Cancer
Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365)
- Condition: Prostatic Neoplasms
- Study ID: NCT02861573
Development of Tissue Predictors of Abiraterone Benefit in Men With mCRPC
- Condition: Metastatic Castration-resistant Prostate Cancer
- Study ID: NCT03176381
Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer
- Condition: Castration Levels of Testosterone, Metastatic Prostatic Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
- Intervention: Drug: Abiraterone, Drug: Bicalutamide, Drug: Degarelix, Drug: Docetaxel, Drug: Flutamide, Drug: Goserelin Acetate, Drug: Histrelin Acetate, Drug: Leuprolide Acetate, Drug: Nilutamide, Procedure: Orchiectomy, Drug: Prednisone, Other: Quality-of-Life Assessment, Radiation: Radiation Therapy, Procedure: Radical Prostatectomy, Drug: Triptorelin
- Study ID: NCT03678025
Cytoreductive Prostatectomy Versus Cytoreductive Prostate Irradiation as a Local Treatment Option for Metastatic Prostate Cancer: a Multicentric Feasibility Trial
- Condition: Prostate Cancer Metastatic
- Study ID: NCT03655886
High Dose Testosterone in Men With Advanced Prostate Cancer and Homologous Recombination Deficiency
- Condition: Castration-resistant Prostate Cancer, Homologous Recombination Deficiency
- Intervention: Drug: Testosterone Enanthate
- Study ID: NCT03522064
Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Condition: Prostate Cancer
- Intervention: Drug: Docetaxel 75 mg/m2, Drug: Docetaxel 60 mg/m2, Drug: Radium-223
- Study ID: NCT03574571
Randomized, Multicentre Phase II Trial of the Sequencing of Radium-223 and Docetaxel Plus Prednisone in Symptomatic Bone-only Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Condition: Metastatic Castration-resistant Prostate Cancer
- Study ID: NCT03230734
177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate Cancer
- Condition: Metastatic Castration Resistant Prostate Cancer (mCRPC)
- Study ID: NCT03874884
A Phase 1/2 Study of Combination Olaparib and Radium-223 in Men With Metastatic Castration-Resistant Prostate Cancer With Bone Metastases (COMRADE)
- Condition: Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma, Prostate Carcinoma Metastatic in the Bone, PSA Level Greater Than or Equal to Two, PSA Progression
- Intervention: Other: Laboratory Biomarker Analysis, Drug: Olaparib, Radiation: Radium Ra 223 Dichloride
- Study ID: NCT03317392
Ice-CAP: A Phase I Trial of Ipatasertib in Combination With Atezolizumab in Patients With Advanced Solid Tumours With PI3K Pathway Hyperactivation
- Condition: Solid Tumor, Glioblastoma Multiforme, Prostate Cancer Metastatic
- Intervention: Drug: ipatasertib, Drug: Atezolizumab
- Study ID: NCT03673787
A Phase 2 Study of a Checkpoint Inhibitor in Men With Progressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation
- Condition: Metastatic Castration Resistant Prostate Cancer
- Intervention: Drug: Pembrolizumab
- Study ID: NCT04104893
Phase II Trial of pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer
- Condition: Castration-resistant Prostate Cancer, Metastatic Cancer, Prostate Cancer
- Intervention: Biological: pTVG-HP, Biological: pTVG-AR, Drug: Pembrolizumab, Drug: rhGM-CSF
- Study ID: NCT04090528
ProBio: An Outcome-adaptive and Randomized Multi-arm Biomarker Driven Study in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
- Condition: Metastatic Castration-Resistant Prostatic Cancer
- Intervention: Drug: Enzalutamide Oral Capsule [Xtandi], Drug: Abiraterone Oral Tablet [Zytiga], Drug: Carboplatin, Drug: Cabazitaxel 60 mg Solution for Injection, Drug: Docetaxel Injectable Solution, Drug: Radium Chloride Ra-223
- Study ID: NCT03903835
An Extended/Phase 2, Multi-Center, Randomized, Open-Label Study to Evaluate the Safety and Tolerability of GT0918 in Subjects With Metastatic Castrate Resistant Prostate Cancer (mCRPC) Who Failed Either Abiraterone or Enzalutamide
- Condition: Metastatic Castrate Resistant Prostate Cancer (mCRPC)
- Intervention: Drug: GT0918
- Study ID: NCT03899467
A Phase 3, Randomized, Double-Blind Study of Nivolumab or Placebo in Combination With Docetaxel, in Men With Metastatic Castration-resistant Prostate Cancer
- Condition: Prostate Cancer
- Intervention: Biological: nivolumab, Drug: prednisone, Drug: docetaxel
- Study ID: NCT04100018
A Phase I Trial of Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer (CRPC)
- Condition: Metastatic Castrate Resistant Prostate Cancer
- Intervention: Drug: Docetaxel, Radiation: Radium 223
- Study ID: NCT03737370
A Phase 1/2 Study of REGN5678 (Anti-PSMAxCD28) With Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-resistant Prostate Cancer
- Condition: Metastatic Castration-resistant Prostate Cancer
- Intervention: Drug: REGN5678, Drug: Cemiplimab
- Study ID: NCT03972657
A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Re
- Condition: Metastatic Castrate Sensitive Prostate Cancer
- Study ID: NCT04497844
A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib+Abiraterone Versus Placebo+Abiraterone as Treatment for Patients With DeNovo Metastatic Hormone-Sensitive Prostate Cancer Characterised by PTE
- Condition: Hormone-Sensitive Prostate Cancer
- Study ID: NCT04493853
Prostate Cancer Biomarker Enrichment and Treatment Selection (PC-BETS) Study
- Condition: Prostate Cancer
- Intervention: Drug: AZD1775, Drug: Savolitinib, Drug: Darolutamide
- Study ID: NCT03385655
A Study to Evaluate the Safety and Efficacy of IMMU-132 (Sacituzumab Govitecan) in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Progressed on Second Generation AR-Directed Therapy
- Condition: Prostate Cancer
- Intervention: Drug: IMMU-132
- Study ID: NCT03725761
Phase I/II Dose-escalation Study of Fractionated and Multiple Dose 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer
- Condition: Prostate Cancer
- Study ID: NCT04506567
A Phase 3, Open-Label, Randomized Study Evaluating Metastatic Castrate Resistant Prostate Cancer Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment (SPLASH)
- Condition: Metastatic Castration-Resistant Prostate Cancer
- Study ID: NCT04647526
A Randomized Phase II Study of 177 LuPSMA-617 vs Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer and PSMA-Positive Disease
- Condition: Prostate Cancer
- Study ID: NCT04663997
Early Detection of Prostate Cancer by Liquid Biopsy
- Condition: Prostate Cancer
- Study ID: NCT04556916
A Phase II Multi-Center Trial of Abemaciclib With or Without Atezolizumab in Metastatic Castration Resistant Prostate Cancer
- Condition: Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
- Study ID: NCT04751929
Local Cytoreductive Treatments for Men With Newly Diagnosed Metastatic Prostate Cancer in Addition to Standard of Care Treatment
- Condition: Prostate Cancer, Metastatic Prostate Cancer
- Intervention: Combination Product: Standard of Care, Procedure: Minimally Invasive Ablative Therapy (MIAT), Procedure: Radical Therapy (Prostatectomy or Radiotherapy)
- Study ID: NCT03763253
A Phase IIA Study of Sequential ("First Strike, Second Strike") Therapies, Modeled on Evolutionary Dynamics of Anthropocene Extinctions, for High Risk Metastatic Castration Sensitive Prostate Cancer
- Condition: Prostate Cancer, Stage IV Prostate Cancer
- Study ID: NCT05189457
A Multi-Center, Open-Label, Randomized Phase 3 Trial Comparing the Safety and Efficacy of 177Lu-PSMA-I&T Versus Hormone Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer
- Condition: Metastasis From Malignant Tumor of Prostate
- Study ID: NCT05204927
A Phase 2, Open-label, Randomized Controlled Trial of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer
- Condition: Prostatic Neoplasms, Castration-Resistant
- Study ID: NCT05169684
A Phase 2 Trial of ADT Interruption in Patients Responding Exceptionally to AR-Pathway Inhibitor in Metastatic Hormone-Sensitive Prostate Cancer (MHSPC): A-DREAM
- Condition: Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
- Study ID: NCT05241860
A Phase I/IIa Theranostic Study of 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer
- Condition: Prostatic Neoplasms, Castration-Resistant
- Study ID: NCT04868604